@misc{10481/72623,
year = {2022},
month = {1},
url = {http://hdl.handle.net/10481/72623},
abstract = {BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a
need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity
for the detection of earlier-stage ovarian cancer.
METHODS: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92
preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched
controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer.
RESULTS: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the
ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancerfree.
All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the
biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did
not improve discrimination compared to CA125 alone.
CONCLUSION: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of
0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of
the markers showed major improvement in discrimination when added to CA125.},
organization = {World Health Organization},
organization = {Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London},
organization = {Danish Cancer Society},
organization = {Ligue Contre le Cancer (France)},
organization = {Institut Gustave Roussy (France)},
organization = {Mutuelle Generale de l'Education Nationale (France)},
organization = {Institut National de la Sante et de la Recherche Medicale (Inserm)},
organization = {Deutsche Krebshilfe},
organization = {German Cancer Research Center (DKFZ) (Germany)},
organization = {German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) (Germany)},
organization = {Federal Ministry of Education & Research (BMBF)},
organization = {Fondazione AIRC per la ricerca sul cancro},
organization = {Compagnia di San Paolo},
organization = {Consiglio Nazionale delle Ricerche (CNR)},
organization = {Netherlands Government},
organization = {World Cancer Research Fund International (WCRF)},
organization = {Netherlands Government},
organization = {Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII) (Spain)},
organization = {Junta de Andalucia},
organization = {Regional Government of Asturias (Spain)},
organization = {Regional Government of Basque Country (Spain)},
organization = {Regional Government of Murcia (Spain)},
organization = {Regional Government of Navarra (Spain)},
organization = {Catalan Institute of OncologyICO (Spain)},
organization = {Swedish Cancer Society},
organization = {Swedish Research Council},
organization = {County Council of Skane (Sweden)},
organization = {County Council of Vasterbotten (Sweden)},
organization = {Cancer Research UK	C864/A14136	
C8221/A29017},
organization = {UK Research & Innovation (UKRI)},
organization = {Medical Research Council UK (MRC)	MR/N003284/1	
MC-UU 12015/1	
MC UU_00006/1	
MR/M012190/1},
organization = {Projekt DEAL},
publisher = {Nature},
title = {Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer},
doi = {10.1038/s41416-021-01697-z},
author = {Mukama, Trasias and Sánchez Pérez, María José},
}